Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edi ...

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy Provided by Business Wire Jun 25, 2025, 4:01:00 AM ...

Director Kevin Buehler of Precision Biosciences INC (NASDAQ: DTIL) recently purchased 5,076 shares of common stock, according to a Form 4 filing. The transactions, which occurred on June 25, 2025 ...

DURHAM, N.C., June 25, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Investing.com -- Precision BioSciences, Inc. (NASDAQ: DTIL) stock surged 17% on Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric ...

DURHAM, N.C., June 25, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies ...

One Biosciences ("One Biosciences" or the "Company"), a precision oncology techbio company pioneering clinical grade single-cell tumor transcriptomic profiling, today announced a €15 million Series A ...

One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro ...

"Synthetic biology tools like optogenetics allow us to precisely tune complex cellular processes, something traditional drug screening cannot do," said Maxwell Wilson, Ph.D., Co-Founder and Chief ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib ...